Cognitive and psychological impact of BRCA genetic counseling in before and after definitive surgery breast cancer patients

Annals of Surgical Oncology

Volumn 19, Issue 13, 2012, Pages 4003-4011

  Christie, Juliette ^a   Quinn, Gwendolyn P ^a,b   Malo, Teri ^a   Lee, Ji Hyun ^a,b   Zhao, Xiuhua ^a   McIntyre, Jessica ^a   Brzosowicz, Jennifer ^a   Jacobsen, Paul B ^a,b   Vadaparampil, Susan T ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CLINICAL DECISION MAKING; CLINICAL TRIAL; COGNITION; FEMALE; GENE MUTATION; GENETIC COUNSELING; HUMAN; MAJOR CLINICAL STUDY; MENTAL STRESS; PATIENT DECISION MAKING; PSYCHOLOGICAL ASPECT; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; COGNITION; CONFLICT (PSYCHOLOGY); DECISION MAKING; FEMALE; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; KNOWLEDGE; MIDDLE AGED; MUTATION; YOUNG ADULT;

EID: 84876479533     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2460-x     Document Type: Article

References (59)

1. Graeser MK, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009;27:5887-92.
2. Malone KE, Begg CB, Haile RW, et al. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. J Clin Oncol. 2010;28:2404-10.
3. Metcalfe KA, Lynch HT, Ghadirian P, et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol. 2005;96:222-6. (Pubitemid 39612440)
4. Chen Y, Thompson W, Semenciw R, Mao Y. Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev. 1999;8:855-61. (Pubitemid 29508719)
5. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1-and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer. 2007;43:867-76. (Pubitemid 46366688)
6. Daly M, Axilbund JE, Bryant E, et al. The NCCN genetic/familial high-risk assessment: breast and ovarian clinical practice guideline, version 1.2006. http://www.nccn.org/. Accessed 1 Oct 2006.
7. Boughey JC, Hoskin TL, Degnim AC, et al. Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol. 2010;17:2702-9.
8. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. J Am Med Assoc. 2010;304:967-75.
9. Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. J Am Med Assoc. 2006;296:185-92.
10. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol. 2004;22:1055-62. (Pubitemid 41095038)
11. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999;91:1475-9. (Pubitemid 29424552)
12. Gronwald J, Tung N, Foulkes WD, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer. 2006;118:2281-4.
13. King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: national surgical adjuvant breast and bowel project (NSABP-P1) breast cancer prevention trial. J Am Med Assoc. 2001;286:2251-6. (Pubitemid 33063147)
14. Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary breast cancer clinical study group. Lancet. 2000;356:1876-81.
15. Daly M, Axilbund JE, Bryant E, et al. The NCCN genetic/familial high-risk assessment: breast and ovarian clinical practice guideline, version 1.2009. http://www.nccn.org/. Accessed 3 Dec 2009.
16. Earle CC. Failing to plan is planning to fail: improving the quality of care with survivorship care plans. J Clin Oncol. 2006;24:5112-6. (Pubitemid 46623196)
17. Hewitt M, Greenfield S, Stovall E. From cancer patient to cancer survivor: lost in transition. Washington, DC: National Academies Press, 2005.
18. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol. 2003;21:2397-406.
19. Robson ME, Storm CD, Weitzel J, et al. American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol. 2010;28:893-901.
20. Berliner JL, Fay AM. Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the national society of genetic counselors. J Genet Couns. 2007;16: 241-60. (Pubitemid 46878636)
21. Fraser FC. Genetic counseling. Am J Hum Genet. 1974;26: 636-61.
22. Bernhardt BA, Biesecker BB, Mastromarino CL. Goals, benefits, and outcomes of genetic counseling: client and genetic counselor assessment. Am J Med Genet. 2000;94:189-97.
23. Shiloh S, Avdor O, Goodman RM. Satisfaction with genetic counseling: dimensions and measurement. Am J Med Genet. 1990;37:522-9. (Pubitemid 20380837)
24. Pilnick A, Dingwall R. Research directions in genetic counselling: a review of the literature. Patient Educ Couns. 2001;44:95-105. (Pubitemid 32677953)
25. Braithwaite D, Emery J, Walter F, et al. Psychological impact of genetic counseling for familial cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2004;96:122-33. (Pubitemid 38195903)
26. Lerman C, Croyle RT, Tercyak KP, Hamann H. Genetic testing: psychological aspects and implications. J Consult Clin Psychol. 2002;70:784-97. (Pubitemid 34640743)
27. Meiser B. Psychological impact of genetic testing for cancer susceptibility: an update of the literature. Psychooncology. 2005;14:1060-74. (Pubitemid 43019695)
28. Hamann HA, Somers TJ, Smith AW, et al. Posttraumatic stress associated with cancer history and BRCA1/2 genetic testing. Psychosom Med. 2005;67:766-72. (Pubitemid 41396024)
29. Vadaparampil ST, Miree CA, Wilson C, Jacobsen PB. Psychosocial and behavioral impact of genetic counseling and testing. Breast Dis. 2007;27:97-108. (Pubitemid 47555190)
30. Schlich-Bakker KJ, Warlam-Rodenhuis CC, Van Echtelt J, et al. Short term psychological distress in patients actively approached for genetic counselling after diagnosis of breast cancer. Eur J Cancer. 2006;42:2722-8. (Pubitemid 44584658)
31. Vadaparampil ST, Quinn GP, Brzosowicz J, Miree CA. Experiences of genetic counseling for BRCA1/2 among recently diagnosed breast cancer patients: a qualitative inquiry. J Psy-chosoc Oncol. 2008;26:33-52.
32. Geer KP, Ropka ME, Cohn WF, et al. Factors influencing patients' decisions to decline cancer genetic counseling services. J Genet Couns. 2001;10:25-40. (Pubitemid 33635905)
33. Nusbaum RH, Peshkin BN, DeMarco TA, Goodenberger M. BRCA 1/2 testing in patients with newly diagnosed breast cancer. Commun Oncol. 2009;6:367-71.
34. Lerman C, Schwartz MD, Lin TH, et al. The influence of psychological distress on use of genetic testing for cancer risk. J Consult Clin Psychol. 1997;65:414-20. (Pubitemid 27246782)
35. Lerman C, Narod S, Schulman K, et al. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. J Am Med Assoc. 1996;275:1885-92. (Pubitemid 26196448)
36. Lerman C, Biesecker B, Benkendorf JL, et al. Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing. J Natl Cancer Inst. 1997;89:148-57. (Pubitemid 27034791)
37. Hopwood P, Shenton A, Lalloo F, et al. Risk perception and cancer worry: an exploratory study of the impact of genetic risk counselling in women with a family history of breast cancer. J Med Genet. 2001;38:139.
38. Horowitz M, Wilner N, Alvarez W. Impact of Event Scale: a measure of subjective stress. Psychosom Med. 1979;41:209-18. (Pubitemid 9219271)
39. Vadaparampil ST, Ropka ME, Stefanek ME. Measurement of psychological factors associated with genetic testing for hereditary breast, ovarian and colon cancers. Fam Cancer. 2005;4:195-206. (Pubitemid 40897824)
40. Wevers MR, Ausems MG, Verhoef S, et al. Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter randomized clinical trial. BMC Cancer. 2011;11:6.
41. Thewes B, Meiser B, Hickie IB. Psychometric properties of the Impact of Event Scale amongst women at increased risk for hereditary breast cancer. Psychooncology. 2001;10:459-68. (Pubitemid 33081032)
42. Schwartz MD, Lerman C, Brogan B, et al. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol. 2004;22:1823-9. (Pubitemid 41095172)
43. O'Connor AM. Validation of a decisional conflict scale. Med Decis Making. 1995;15:25-30.
44. O'Connor AM. User manual-decisional conflict scale. Ottawa: Ottawa Hospital Research Institute, 1993, updated 2010.
45. Cranney A, O'Connor AM, Jacobsen MJ, et al. Development and pilot testing of a decision aid for postmenopausal women with osteoporosis. Patient Educ Couns. 2002;47:245-55. (Pubitemid 34667203)
46. Man-Son-Hing M, Laupacis A, O'Connor AM, et al. A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial. J Am Med Assoc. 1999;282:737-43. (Pubitemid 29404379)
47. Stacey D, DeGrasse C, Johnston L. Addressing the support needs of women at high risk for breast cancer: evidence-based care by advanced practice nurses. Oncol Nurs Forum. 2002;29:E77-84.
48. Sawka CA, Goel V, Mahut CA, et al. Development of a patient decision aid for choice of surgical treatment for breast cancer. Health Expect. 1998;1:23-36.
49. O'Connor AM, Tugwell P, Wells GA, et al. A decision aid for women considering hormone therapy after menopause: decision support framework and evaluation. Patient Educ Couns. 1998;33:267-79. (Pubitemid 28168092)
50. O'Connor AM, Tugwell P, Wells GA, et al. Randomized trial of a portable, self-administered decision aid for postmenopausal women considering long-term preventive hormone therapy. Med Decis Making. 1998;18:295-303. (Pubitemid 28307560)
51. Trivers KF, Baldwin LM, Miller JW, et al. Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a vignette-based study. Cancer. 2011;117:5334-43.
52. Meyer LA, Anderson ME, Lacour RA, et al. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstet Gynecol. 2010;115:945-52.
53. Vadaparampil ST, Quinn GP, Miree CA, et al. Recall of and reactions to a surgeon referral letter for BRCA genetic counseling among high-risk breast cancer patients. Ann Surg Oncol. 2009;16:1973-81.
54. O'Neill SM, Peters JA, Vogel VG, et al. Referral to cancer genetic counseling: are there stages of readiness? Am J Med Genet C Semin Med Genet. 2006;142C:221-31. (Pubitemid 44747449)
55. Levy DE, Byfield SD, Comstock CB, et al. Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk. Genet Med. 2011;13: 349-55.
56. Clarke A, Parsons E, Williams A. Outcomes and process in genetic counselling. Clin Genet. 1996;50:462-9. (Pubitemid 27075354)
57. Bowen DJ, Burke W, McTiernan A, et al. Breast cancer risk counseling improves women's functioning. Patient Educ Couns. 2004;53:79-86. (Pubitemid 38519989)
58. Meiser B, Halliday JL. What is the impact of genetic counselling in women at increased risk of developing hereditary breast cancer? A meta-analytic review. Soc Sci Med. 2002;54:1463-70. (Pubitemid 34309011)
59. Bellcross CA, Kolor K, Goddard KA, et al. Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians. Am J Prev Med. 2011;40:61-6.